{"id":20,"date":"2025-01-03T14:32:24","date_gmt":"2025-01-03T13:32:24","guid":{"rendered":"https:\/\/syoligo.sylentis.com\/?page_id=20"},"modified":"2025-02-11T10:54:42","modified_gmt":"2025-02-11T09:54:42","slug":"proyecto-syoligo","status":"publish","type":"page","link":"https:\/\/syoligo.sylentis.com\/es\/proyecto-syoligo\/","title":{"rendered":"Proyecto Syoligo"},"content":{"rendered":"\n  <div class=\"banner has-hover\" id=\"banner-1637437670\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1434\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/Syoligo-arn-cadena-enfermedades-raras-imagen-sylentis-8-scaled.jpg\" class=\"bg attachment-original size-original\" alt=\"\" \/>                        <div class=\"overlay\"><\/div>            \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n   <div id=\"text-box-1410187900\" class=\"text-box banner-layer x50 md-x50 lg-x50 y65 md-y65 lg-y65 res-text\">\n                     <div data-animate=\"fadeInUp\">           <div class=\"text-box-content text \">\n              \n              <div class=\"text-inner text-center\">\n                  \n<h2>Proyecto SYOLIGO<\/h2>\n              <\/div>\n           <\/div>\n       <\/div>                     \n<style>\n#text-box-1410187900 {\n  width: 85%;\n}\n#text-box-1410187900 .text-box-content {\n  font-size: 100%;\n}\n@media (min-width:550px) {\n  #text-box-1410187900 {\n    width: 90%;\n  }\n}\n<\/style>\n    <\/div>\n \n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1637437670 {\n  padding-top: 350px;\n  background-color: rgb(1, 47, 91);\n}\n#banner-1637437670 .overlay {\n  background-color: rgba(1, 47, 91, 0.547);\n}\n<\/style>\n  <\/div>\n\n\n\n\t<section class=\"section\" id=\"section_302635910\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:rgb(235, 235, 235);border-width:1px 0px 0px 0px;\">\n\t<\/div>\n\n\t\t<\/div>\n\n\t\t\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row row-collapse row-full-width align-middle align-center\"  id=\"row-1713008309\">\n\n\t<div id=\"col-1673040979\" class=\"col medium-5 small-12 large-3\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_28765858\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1428\" height=\"793\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/Logotipo-SYOLIGO-med4cure-2.png\" class=\"attachment-original size-original\" alt=\"\" srcset=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/Logotipo-SYOLIGO-med4cure-2.png 1428w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/Logotipo-SYOLIGO-med4cure-2-300x167.png 300w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/Logotipo-SYOLIGO-med4cure-2-1024x569.png 1024w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/Logotipo-SYOLIGO-med4cure-2-768x426.png 768w\" sizes=\"auto, (max-width: 1428px) 100vw, 1428px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_28765858 {\n  width: 82%;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-875593069\" class=\"col medium-7 small-12 large-4\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-25807805\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-25807805 {\n  padding-top: 45px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2 style=\"text-align: center;\"><span style=\"font-size: 150%;\" data-text-color=\"success\"><strong>\u00bfQu\u00e9 es <span data-text-color=\"secondary\">SYOLIGO<\/span>?<\/strong><\/span><\/h2>\n\t<div id=\"text-990524320\" class=\"text\">\n\t\t\n<p><span data-text-color=\"secondary\"><strong>SYOLIGO<\/strong><\/span> es un proyecto de I+D y Primer Despliegue Industrial llevado a cabo por Sylentis para el desarrollo y fabricaci\u00f3n sostenible de terapias basadas en RNA dirigidas a enfermedades raras en Espa\u00f1a y en Europa.<\/p>\n\t\t\n<style>\n#text-990524320 {\n  text-align: left;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-1713008309 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_302635910 {\n  padding-top: 20px;\n  padding-bottom: 20px;\n  background-color: rgb(245, 245, 245);\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section arnfondogris hide-for-small\" id=\"section_1119786001\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\t<div class=\"ux-shape-divider ux-shape-divider--top ux-shape-divider--style-arrow-2\">\n\t\t<svg viewBox=\"0 0 1000 100\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n\t<path class=\"ux-shape-fill\" d=\"M1000 100H0L0 96H480.929C482.255 96 483.527 95.4732 484.464 94.5355L497.879 81.1213C499.05 79.9497 500.95 79.9497 502.121 81.1213L515.536 94.5355C516.473 95.4732 517.745 96 519.071 96H1000V100Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t<div class=\"ux-shape-divider ux-shape-divider--bottom ux-shape-divider--style-waves-opacity-3\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n\t<path class=\"ux-shape-fill\" opacity=\"0.05\" d=\"M1014 264V386H206L34 300C34 300 344.42 277.16 436 221C542 156 590 160 704 209C811 255 899.11 214.94 979 346L1014 264Z\"\/>\n\t<path class=\"ux-shape-fill\" opacity=\"0.1\" d=\"M-302 55C-302 55 -66.73 263.25 50 214C178 160 283 116 353 141C445.68 174.1 534.28 256.19 588 249C692.9 235 764.52 75.94 855 131C940.61 183.09 1000 254 1000 254V328L-306 338L-302 55Z\"\/>\n\t<path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M-286 255C-286 255 -72 152 52 126C176 100 255 155 436 227C581.57 284.91 614.7 277.79 708 227C787 184 1009 3.0001 1093 164C1146 265.63 1031 293 1031 293L924 377L-288 389L-286 255Z\"\/>\n\t<path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M-24 69C-24 69 275.68 370.66 389 314C397 310 622 316 673 356C690.47 369.7 845 224 890 182C944.8 130.85 1018 92 1078 143C1154.12 207.7 1196 242 1196 242L1184 374L-28 386L-24 69Z\"\/>\n\t<path class=\"ux-shape-fill\" d=\"M-12 201C-12 201 58 284 182 258C306 232 342.29 221.23 456 264C565 305 640.82 288.36 721 249C776 222 837.5 191.31 935 253C984 284 1030 279 1030 279L1024 430L-12 440V201Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n\t<div id=\"gap-626670331\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-626670331 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row align-center\" style=\"max-width:80%\" id=\"row-1174649348\">\n\n\t<div id=\"col-2023133868\" class=\"col medium-12 small-12 large-6\"  data-animate=\"fadeInRight\">\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgba(1, 47, 91, 0.913);\" >\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:#bad63d;border-radius:10px;border-width:3px 0px 0px 0px;\">\n\t<\/div>\n\t\t\t\n\n\t\t<div class=\"icon-box featured-box icon-box-left text-left\"  >\n\t\t\t\t\t<div class=\"icon-box-img\" style=\"width: 60px\">\n\t\t\t\t<div class=\"icon\">\n\t\t\t\t\t<div class=\"icon-inner\" style=\"color:rgb(255, 255, 255);\">\n\t\t\t\t\t\t<?xml version=\"1.0\" encoding=\"UTF-8\"?> <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" version=\"1.0\" id=\"Layer_1\" x=\"0px\" y=\"0px\" viewBox=\"0 0 64 64\" style=\"enable-background:new 0 0 64 64;\" xml:space=\"preserve\"> <style type=\"text\/css\"> .st0{fill:none;stroke:#231F20;stroke-width:2;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:10;} <\/style> <g> <path class=\"st0\" d=\"M46,6.6h5.3c2.3,0,4.2,1.9,4.2,4.3v46.5c0,2.4-1.9,4.3-4.2,4.3H12.7c-2.3,0-4.2-1.9-4.2-4.3V11 c0-2.4,1.9-4.3,4.2-4.3h5.3\"><\/path> <path class=\"st0\" d=\"M43.7,11.1H20.3c-1.3,0-2.3-1-2.3-2.3V4.5c0-1.3,1-2.3,2.3-2.3h23.3c1.3,0,2.3,1,2.3,2.3v4.3 C45.9,10.1,44.9,11.1,43.7,11.1z\"><\/path> <polygon class=\"st0\" points=\"28.3,19.8 24.4,22.1 24.4,26.7 28.3,28.9 32.1,26.7 32.1,22.1 \"><\/polygon> <polygon class=\"st0\" points=\"32.1,26.7 28.3,28.9 28.3,33.5 32.1,35.7 36,33.5 36,28.9 \"><\/polygon> <polygon class=\"st0\" points=\"36,19.8 32.1,22.1 32.1,26.7 36,28.9 39.8,26.7 39.8,22.1 \"><\/polygon> <line class=\"st0\" x1=\"28.3\" y1=\"19.8\" x2=\"28.3\" y2=\"15.8\"><\/line> <line class=\"st0\" x1=\"36\" y1=\"19.8\" x2=\"36\" y2=\"15.8\"><\/line> <line class=\"st0\" x1=\"24.4\" y1=\"22.1\" x2=\"20.5\" y2=\"22.1\"><\/line> <line class=\"st0\" x1=\"28.3\" y1=\"33.5\" x2=\"24.3\" y2=\"33.5\"><\/line> <line class=\"st0\" x1=\"43.8\" y1=\"26.7\" x2=\"39.8\" y2=\"26.7\"><\/line> <line class=\"st0\" x1=\"32.1\" y1=\"39.8\" x2=\"32.1\" y2=\"35.7\"><\/line> <line class=\"st0\" x1=\"16\" y1=\"46.4\" x2=\"48\" y2=\"46.4\"><\/line> <line class=\"st0\" x1=\"16\" y1=\"53\" x2=\"48\" y2=\"53\"><\/line> <\/g> <\/svg> \t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t<div class=\"icon-box-text last-reset\">\n\t\t\t\t\t\t\t\t\t\n<p><span data-text-color=\"secondary\"><strong>Marco temporal &#8211;<\/strong><\/span>\u00a0<span style=\"color: #ffffff;\">Con una duraci\u00f3n <b>desde el a\u00f1o 2023 al 2030<\/b>, SYOLIGO establece las bases tecnol\u00f3gicas e instalaciones necesarias para hacer de Sylentis una industria biofarmac\u00e9utica l\u00edder en la UE en el desarrollo y la fabricaci\u00f3n de productos basados en \u00e1cidos nucleicos de RNA.<\/span><\/p>\n\t\t<\/div>\n\t<\/div>\n\t\n\t\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-2023133868 > .col-inner {\n  padding: 4% 4% 4% 4%;\n  border-radius: 14px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-732824214\" class=\"col medium-12 small-12 large-6\"  data-animate=\"fadeInLeft\">\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:#1b4169;border-radius:10px;border-width:3px 3px 3px 3px;\">\n\t<\/div>\n\t\t\t\n\n\t\t<div class=\"tabbed-content\">\n\t\t\t\n\t\t\t<ul class=\"nav nav-tabs nav-normal nav-size-xlarge nav-center active-on-hover\" role=\"tablist\"><li id=\"tab-visi\u00f3n\" class=\"tab active has-icon\" role=\"presentation\"><a href=\"#tab_visi\u00f3n\" role=\"tab\" aria-selected=\"true\" aria-controls=\"tab_visi\u00f3n\"><span>Visi\u00f3n<\/span><\/a><\/li>\n<li id=\"tab-misi\u00f3n\" class=\"tab has-icon\" role=\"presentation\"><a href=\"#tab_misi\u00f3n\" tabindex=\"-1\" role=\"tab\" aria-selected=\"false\" aria-controls=\"tab_misi\u00f3n\"><span>Misi\u00f3n<\/span><\/a><\/li>\n<li id=\"tab-objetivos\" class=\"tab has-icon\" role=\"presentation\"><a href=\"#tab_objetivos\" tabindex=\"-1\" role=\"tab\" aria-selected=\"false\" aria-controls=\"tab_objetivos\"><span>Objetivos<\/span><\/a><\/li><\/ul><div class=\"tab-panels\"><div id=\"tab_visi\u00f3n\" class=\"panel active entry-content\" role=\"tabpanel\" aria-labelledby=\"tab-visi\u00f3n\">\n\t<div id=\"text-3113524799\" class=\"text\">\n\t\t\n<p>Sylentis, con el proyecto <span data-text-color=\"secondary\"><strong>SYOLIGO<\/strong><\/span>, busca <span style=\"font-weight: 400;\">convertirse en un <strong>referente europeo en la producci\u00f3n sostenible de oligonucle\u00f3tidos<\/strong>,<\/span> fomentar nuevas<strong> aproximaciones terap\u00e9uticas con oligonucle\u00f3tidos de RNA dirigidas a enfermedades raras<\/strong> y convertirse en un referente europeo en la producci\u00f3n sostenible de oligonucle\u00f3tidos.<\/p>\n\t\t\n<style>\n#text-3113524799 {\n  line-height: 2.05;\n  text-align: center;\n  color: #012f5b;\n}\n#text-3113524799 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<\/div>\n<div id=\"tab_misi\u00f3n\" class=\"panel entry-content\" role=\"tabpanel\" aria-labelledby=\"tab-misi\u00f3n\">\n\t<div id=\"text-1195433796\" class=\"text\">\n\t\t\n<p><span data-text-color=\"secondary\"><strong>SYOLIGO<\/strong><\/span> <strong>reforzar\u00e1 la base tecnol\u00f3gica y habilitar\u00e1 las instalaciones necesarias para apoyar el crecimiento sostenible de Sylentis<\/strong> como una empresa farmac\u00e9utica l\u00edder en la UE especializada en el desarrollo y la fabricaci\u00f3n de productos basados en \u00e1cidos nucleicos de RNA.<\/p>\n\t\t\n<style>\n#text-1195433796 {\n  text-align: center;\n  color: #012f5b;\n}\n#text-1195433796 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<\/div>\n<div id=\"tab_objetivos\" class=\"panel entry-content\" role=\"tabpanel\" aria-labelledby=\"tab-objetivos\">\n\t<div id=\"text-2905120293\" class=\"text\">\n\t\t\n<h3 style=\"text-align: center;\"><span data-text-color=\"secondary\"><strong>Investigaci\u00f3n y desarrollo (I+D)<\/strong><\/span><\/h3>\n<ul>\n<li>Desarrollar terapias basadas en RNA para el <strong>tratamiento m\u00e1s eficiente dirigido a enfermedades raras<\/strong>.<\/li>\n<li><strong>Colaborar activamente con los socios del IPCEI<\/strong>.<\/li>\n<\/ul>\n\t\t\n<style>\n#text-2905120293 {\n  color: #012f5b;\n}\n#text-2905120293 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-1987409403\" class=\"text\">\n\t\t\n<h3 style=\"text-align: center;\"><span data-text-color=\"secondary\">Primer despliegue industrial (FID)<\/span><\/h3>\n<ul>\n<li>Puesta a punto de una <strong>nueva planta de producci\u00f3n sostenible<\/strong> de oligonucle\u00f3tidos en Espa\u00f1a.<\/li>\n<li><strong>Reducci\u00f3n del par\u00e1metro de sostenibilidad PMI <\/strong>del proceso de fabricaci\u00f3n de oligonucle\u00f3tidos.<\/li>\n<li><strong>Introducci\u00f3n de procesos innovadores<\/strong> de producci\u00f3n de oligonucle\u00f3tidos.<\/li>\n<\/ul>\n\t\t\n<style>\n#text-1987409403 {\n  color: #012f5b;\n}\n#text-1987409403 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<\/div><\/div><\/div>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-732824214 > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_1119786001 {\n  padding-top: 60px;\n  padding-bottom: 60px;\n}\n#section_1119786001 .ux-shape-divider--top svg {\n  height: 150px;\n  --divider-top-width: 100%;\n}\n#section_1119786001 .ux-shape-divider--top .ux-shape-fill {\n  fill: #b9d63e;\n}\n#section_1119786001 .ux-shape-divider--bottom svg {\n  height: 50px;\n  --divider-width: 100%;\n}\n#section_1119786001 .ux-shape-divider--bottom .ux-shape-fill {\n  fill: #b9d63e;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section arnfondogris show-for-small\" id=\"section_937990253\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\t<div class=\"ux-shape-divider ux-shape-divider--top ux-shape-divider--style-arrow-2\">\n\t\t<svg viewBox=\"0 0 1000 100\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n\t<path class=\"ux-shape-fill\" d=\"M1000 100H0L0 96H480.929C482.255 96 483.527 95.4732 484.464 94.5355L497.879 81.1213C499.05 79.9497 500.95 79.9497 502.121 81.1213L515.536 94.5355C516.473 95.4732 517.745 96 519.071 96H1000V100Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t<div class=\"ux-shape-divider ux-shape-divider--bottom ux-shape-divider--style-waves-opacity-3\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n\t<path class=\"ux-shape-fill\" opacity=\"0.05\" d=\"M1014 264V386H206L34 300C34 300 344.42 277.16 436 221C542 156 590 160 704 209C811 255 899.11 214.94 979 346L1014 264Z\"\/>\n\t<path class=\"ux-shape-fill\" opacity=\"0.1\" d=\"M-302 55C-302 55 -66.73 263.25 50 214C178 160 283 116 353 141C445.68 174.1 534.28 256.19 588 249C692.9 235 764.52 75.94 855 131C940.61 183.09 1000 254 1000 254V328L-306 338L-302 55Z\"\/>\n\t<path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M-286 255C-286 255 -72 152 52 126C176 100 255 155 436 227C581.57 284.91 614.7 277.79 708 227C787 184 1009 3.0001 1093 164C1146 265.63 1031 293 1031 293L924 377L-288 389L-286 255Z\"\/>\n\t<path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M-24 69C-24 69 275.68 370.66 389 314C397 310 622 316 673 356C690.47 369.7 845 224 890 182C944.8 130.85 1018 92 1078 143C1154.12 207.7 1196 242 1196 242L1184 374L-28 386L-24 69Z\"\/>\n\t<path class=\"ux-shape-fill\" d=\"M-12 201C-12 201 58 284 182 258C306 232 342.29 221.23 456 264C565 305 640.82 288.36 721 249C776 222 837.5 191.31 935 253C984 284 1030 279 1030 279L1024 430L-12 440V201Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n\t<div id=\"gap-44431037\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-44431037 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row row-full-width align-center\"  id=\"row-1861893980\">\n\n\t<div id=\"col-1654381053\" class=\"col medium-12 small-12 large-6\"  data-animate=\"fadeInRight\">\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgba(1, 47, 91, 0.913);\" >\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:#bad63d;border-radius:10px;border-width:3px 0px 0px 0px;\">\n\t<\/div>\n\t\t\t\n\n\t\t<div class=\"icon-box featured-box icon-box-left text-left\"  >\n\t\t\t\t\t<div class=\"icon-box-img\" style=\"width: 60px\">\n\t\t\t\t<div class=\"icon\">\n\t\t\t\t\t<div class=\"icon-inner\" style=\"color:rgb(255, 255, 255);\">\n\t\t\t\t\t\t<?xml version=\"1.0\" encoding=\"UTF-8\"?> <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" version=\"1.0\" id=\"Layer_1\" x=\"0px\" y=\"0px\" viewBox=\"0 0 64 64\" style=\"enable-background:new 0 0 64 64;\" xml:space=\"preserve\"> <style type=\"text\/css\"> .st0{fill:none;stroke:#231F20;stroke-width:2;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:10;} <\/style> <g> <path class=\"st0\" d=\"M46,6.6h5.3c2.3,0,4.2,1.9,4.2,4.3v46.5c0,2.4-1.9,4.3-4.2,4.3H12.7c-2.3,0-4.2-1.9-4.2-4.3V11 c0-2.4,1.9-4.3,4.2-4.3h5.3\"><\/path> <path class=\"st0\" d=\"M43.7,11.1H20.3c-1.3,0-2.3-1-2.3-2.3V4.5c0-1.3,1-2.3,2.3-2.3h23.3c1.3,0,2.3,1,2.3,2.3v4.3 C45.9,10.1,44.9,11.1,43.7,11.1z\"><\/path> <polygon class=\"st0\" points=\"28.3,19.8 24.4,22.1 24.4,26.7 28.3,28.9 32.1,26.7 32.1,22.1 \"><\/polygon> <polygon class=\"st0\" points=\"32.1,26.7 28.3,28.9 28.3,33.5 32.1,35.7 36,33.5 36,28.9 \"><\/polygon> <polygon class=\"st0\" points=\"36,19.8 32.1,22.1 32.1,26.7 36,28.9 39.8,26.7 39.8,22.1 \"><\/polygon> <line class=\"st0\" x1=\"28.3\" y1=\"19.8\" x2=\"28.3\" y2=\"15.8\"><\/line> <line class=\"st0\" x1=\"36\" y1=\"19.8\" x2=\"36\" y2=\"15.8\"><\/line> <line class=\"st0\" x1=\"24.4\" y1=\"22.1\" x2=\"20.5\" y2=\"22.1\"><\/line> <line class=\"st0\" x1=\"28.3\" y1=\"33.5\" x2=\"24.3\" y2=\"33.5\"><\/line> <line class=\"st0\" x1=\"43.8\" y1=\"26.7\" x2=\"39.8\" y2=\"26.7\"><\/line> <line class=\"st0\" x1=\"32.1\" y1=\"39.8\" x2=\"32.1\" y2=\"35.7\"><\/line> <line class=\"st0\" x1=\"16\" y1=\"46.4\" x2=\"48\" y2=\"46.4\"><\/line> <line class=\"st0\" x1=\"16\" y1=\"53\" x2=\"48\" y2=\"53\"><\/line> <\/g> <\/svg> \t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t<div class=\"icon-box-text last-reset\">\n\t\t\t\t\t\t\t\t\t\n<p><span data-text-color=\"secondary\"><strong>Marco temporal &#8211;<\/strong><\/span>\u00a0<span style=\"color: #ffffff;\">Con una duraci\u00f3n <b>desde el a\u00f1o 2023 al 2030<\/b>, SYOLIGO establece las bases tecnol\u00f3gicas e instalaciones necesarias para hacer de Sylentis una industria biofarmac\u00e9utica l\u00edder en la UE en el desarrollo y la fabricaci\u00f3n de productos basados en \u00e1cidos nucleicos de RNA.<\/span><\/p>\n\t\t<\/div>\n\t<\/div>\n\t\n\t\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1654381053 > .col-inner {\n  padding: 4% 4% 4% 4%;\n  border-radius: 14px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1803176424\" class=\"col medium-12 small-12 large-6\"  data-animate=\"fadeInLeft\">\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t<div class=\"is-border\"\n\t\tstyle=\"border-color:#1b4169;border-radius:10px;border-width:3px 3px 3px 3px;\">\n\t<\/div>\n\t\t\t\n\n\t\t<div class=\"tabbed-content\">\n\t\t\t\n\t\t\t<ul class=\"nav nav-tabs nav-normal nav-size-xlarge nav-center active-on-hover\" role=\"tablist\"><li id=\"tab-visi\u00f3n\" class=\"tab active has-icon\" role=\"presentation\"><a href=\"#tab_visi\u00f3n\" role=\"tab\" aria-selected=\"true\" aria-controls=\"tab_visi\u00f3n\"><span>Visi\u00f3n<\/span><\/a><\/li>\n<li id=\"tab-misi\u00f3n\" class=\"tab has-icon\" role=\"presentation\"><a href=\"#tab_misi\u00f3n\" tabindex=\"-1\" role=\"tab\" aria-selected=\"false\" aria-controls=\"tab_misi\u00f3n\"><span>Misi\u00f3n<\/span><\/a><\/li>\n<li id=\"tab-objetivos\" class=\"tab has-icon\" role=\"presentation\"><a href=\"#tab_objetivos\" tabindex=\"-1\" role=\"tab\" aria-selected=\"false\" aria-controls=\"tab_objetivos\"><span>Objetivos<\/span><\/a><\/li><\/ul><div class=\"tab-panels\"><div id=\"tab_visi\u00f3n\" class=\"panel active entry-content\" role=\"tabpanel\" aria-labelledby=\"tab-visi\u00f3n\">\n\t<div id=\"text-1112421656\" class=\"text\">\n\t\t\n<p>Sylentis, con el proyecto <span data-text-color=\"secondary\"><strong>SYOLIGO<\/strong><\/span>, busca <span style=\"font-weight: 400;\">convertirse en un <strong>referente europeo en la producci\u00f3n sostenible de oligonucle\u00f3tidos<\/strong>,<\/span> fomentar nuevas<strong> aproximaciones terap\u00e9uticas con oligonucle\u00f3tidos de RNA dirigidas a enfermedades raras<\/strong> y convertirse en un referente europeo en la producci\u00f3n sostenible de oligonucle\u00f3tidos.<\/p>\n\t\t\n<style>\n#text-1112421656 {\n  line-height: 2.05;\n  text-align: center;\n  color: #012f5b;\n}\n#text-1112421656 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<\/div>\n<div id=\"tab_misi\u00f3n\" class=\"panel entry-content\" role=\"tabpanel\" aria-labelledby=\"tab-misi\u00f3n\">\n\t<div id=\"text-2471641959\" class=\"text\">\n\t\t\n<p><span data-text-color=\"secondary\"><strong>SYOLIGO<\/strong><\/span> <strong>crear\u00e1 la base tecnol\u00f3gica y habilitar\u00e1 las instalaciones necesarias para hacer crecer de forma sostenible a Sylentis<\/strong> como una industria farmac\u00e9utica l\u00edder en la UE para el desarrollo y la fabricaci\u00f3n de productos basados en \u00e1cidos nucleicos de RNA.<\/p>\n\t\t\n<style>\n#text-2471641959 {\n  text-align: center;\n  color: #012f5b;\n}\n#text-2471641959 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<\/div>\n<div id=\"tab_objetivos\" class=\"panel entry-content\" role=\"tabpanel\" aria-labelledby=\"tab-objetivos\">\n\t<div id=\"text-134118454\" class=\"text\">\n\t\t\n<h3 style=\"text-align: center;\"><span data-text-color=\"secondary\"><strong>Investigaci\u00f3n y desarrollo (I+D)<\/strong><\/span><\/h3>\n<ul>\n<li>Desarrollar terapias basadas en RNA para el <strong>tratamiento m\u00e1s eficiente dirigido a enfermedades raras<\/strong>.<\/li>\n<li><strong>Colaborar activamente con los socios del IPCEI<\/strong>.<\/li>\n<\/ul>\n\t\t\n<style>\n#text-134118454 {\n  color: #012f5b;\n}\n#text-134118454 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-1705528535\" class=\"text\">\n\t\t\n<h3 style=\"text-align: center;\"><span data-text-color=\"secondary\">Primer despliegue industrial (FID)<\/span><\/h3>\n<ul>\n<li>Puesta a punto de una <strong>nueva planta de producci\u00f3n sostenible<\/strong> de oligonucle\u00f3tidos en Espa\u00f1a.<\/li>\n<li><strong>Reducci\u00f3n del par\u00e1metro de sostenibilidad PMI <\/strong>del proceso de fabricaci\u00f3n de oligonucle\u00f3tidos.<\/li>\n<li><strong>Introducci\u00f3n de procesos innovadores<\/strong> de producci\u00f3n de oligonucle\u00f3tidos.<\/li>\n<\/ul>\n\t\t\n<style>\n#text-1705528535 {\n  color: #012f5b;\n}\n#text-1705528535 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<\/div><\/div><\/div>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1803176424 > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_937990253 {\n  padding-top: 60px;\n  padding-bottom: 60px;\n}\n#section_937990253 .ux-shape-divider--top svg {\n  height: 150px;\n  --divider-top-width: 100%;\n}\n#section_937990253 .ux-shape-divider--top .ux-shape-fill {\n  fill: #b9d63e;\n}\n#section_937990253 .ux-shape-divider--bottom svg {\n  height: 50px;\n  --divider-width: 100%;\n}\n#section_937990253 .ux-shape-divider--bottom .ux-shape-fill {\n  fill: #b9d63e;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section hide-for-small\" id=\"section_1899264283\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\t<div class=\"ux-shape-divider ux-shape-divider--top ux-shape-divider--style-waves-opacity-2 ux-shape-divider--flip ux-shape-divider--to-front\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t<div class=\"ux-shape-divider ux-shape-divider--bottom ux-shape-divider--style-waves-opacity-2 ux-shape-divider--flip ux-shape-divider--to-front\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row row-collapse align-middle\" style=\"max-width:80%\" id=\"row-1571098733\">\n\n\t<div id=\"col-2096375406\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:#012f5b;\" >\n\t\t\t\n\t\t\t\n<div class=\"row row-collapse row-full-width align-middle align-center\"  id=\"row-182498848\">\n\n\t<div id=\"col-1831192709\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner text-left\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-4276285014\" class=\"text\">\n\t\t\n<h2 style=\"text-align: center;\"><span data-text-color=\"secondary\">F\u00e1rmacos basados en RNA<\/span><\/h2>\n\t\t\n<style>\n#text-4276285014 {\n  text-align: center;\n  color: #5f5e5c;\n}\n#text-4276285014 > * {\n  color: #5f5e5c;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-182498848 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n<div class=\"row row-collapse row-full-width align-middle\"  id=\"row-968491507\">\n\n\t<div id=\"col-722796041\" class=\"col medium-12 small-12 large-5\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-3220635444\" class=\"text\">\n\t\t\n<p><strong>Las terapias basadas en oligonucle\u00f3tidos han supuesto una revoluci\u00f3n en la medicina<\/strong> debido a su capacidad para controlar con precisi\u00f3n la producci\u00f3n de una prote\u00edna asociada a una enfermedad, corregir una mutaci\u00f3n y dirigirse a una variedad de v\u00edas y dianas terap\u00e9uticas antes sin opciones de tratamiento.<\/p>\n<p>La elevada tasa de \u00e9xito de las autoridades reguladoras a la hora de aprobar este tipo de medicamentos demuestra esta r\u00e1pida expansi\u00f3n (FDA y EMA). <strong>Las terapias basadas en RNA han producido recientemente tratamientos aprobados por la FDA y la EMA para trastornos metab\u00f3licos y degenerativos extremadamente raros que abordan de forma significativa necesidades m\u00e9dicas no cubiertas y tienen un alto valor terap\u00e9utico<\/strong> (coste anual del tratamiento entre 400 000 y 800 000 euros). De hecho, se ha progresado hasta el punto de que, en los \u00faltimos cinco a\u00f1os, se han autorizado medicamentos cada a\u00f1o, lo que representa el 7% de los medicamentos aprobados por la FDA en 2023.<\/p>\n\t\t\n<style>\n#text-3220635444 {\n  color: rgb(255,255,255);\n}\n#text-3220635444 > * {\n  color: rgb(255,255,255);\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1533937015\" class=\"col medium-12 large-7\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t\t\t\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1454959527\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"3022\" height=\"806\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602.png\" class=\"attachment-original size-original\" alt=\"\" srcset=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602.png 3022w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-300x80.png 300w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-1024x273.png 1024w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-768x205.png 768w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-1536x410.png 1536w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-2048x546.png 2048w\" sizes=\"auto, (max-width: 3022px) 100vw, 3022px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1454959527 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-1851644825\" class=\"text\">\n\t\t\n<p><span style=\"font-size: 90%;\">* Infograf\u00eda extra\u00edda de la <strong>gu\u00eda <em>Descubriendo los oligonucle\u00f3tidos terap\u00e9uticos <\/em>de OLIGOFASTX<\/strong><\/span><\/p>\n\t\t\n<style>\n#text-1851644825 {\n  text-align: left;\n  color: #012f5b;\n}\n#text-1851644825 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<a href=\"https:\/\/oligofastx.com\/es\/descubriendo-oligonucleotidos\/\" target=\"_blank\" class=\"button secondary\" rel=\"noopener\"  style=\"border-radius:99px;\">\n\t\t<span>acceder a la descarga de la gu\u00eda<\/span>\n\t<\/a>\n\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1533937015 > .col-inner {\n  padding: 1% 1% 1% 1%;\n  border-radius: 10px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n<style>\n#row-968491507 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n<div class=\"row row-collapse row-full-width\"  id=\"row-893498199\">\n\n\t<div id=\"col-1886355926\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"accordion acordeoncolor\">\n\t<div id=\"accordion-1310863849\" class=\"accordion-item\">\n\t\t<a id=\"accordion-1310863849-label\" class=\"accordion-title plain\" href=\"#accordion-item-m\u00e1s-informaci\u00f3n\" aria-expanded=\"false\" aria-controls=\"accordion-1310863849-content\" >\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\"><\/i><\/button>\n\t\t\t<span>M\u00e1s informaci\u00f3n<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-1310863849-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-1310863849-label\" >\n\t\t\t\n<div class=\"row row-small row-full-width align-equal\"  id=\"row-1567721791\">\n\n\t<div id=\"col-1112730030\" class=\"col medium-7 small-12 large-7\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t\t\t\n\t<div id=\"text-306877341\" class=\"text\">\n\t\t\n<p>El compromiso adquirido por las agencias reguladoras tanto europeas como norteamericanas con las terapias con oligonucle\u00f3tidos de ARN para el tratamiento de enfermedades raras y <strong>la legislaci\u00f3n articulada como el Reglamento 141\/2000 de la Ley de Medicamentos Hu\u00e9rfanos en la UE, ha dado lugar a cientos de nuevos medicamentos hu\u00e9rfanos, la mayor\u00eda enfermedades raras<\/strong>. Las terapias basadas en oligonucle\u00f3tidos son una de las mejores herramientas para el desarrollo de terapias que satisfagan las necesidades de enfermedades raras muy complejas, gracias a su versatilidad y especificidad, y se ha abierto un camino sin retorno.<\/p>\n\t\t\n<style>\n#text-306877341 {\n  color: #012f5b;\n}\n#text-306877341 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-2693104343\" class=\"text\">\n\t\t\n<p><strong>En la actualidad hay 21 medicamentos basados en oligonucle\u00f3tidos aprobados para muchas enfermedades diferentes y muchos m\u00e1s en fase de investigaci\u00f3n<\/strong>. La misi\u00f3n de Sylentis con SYOLIGO sopone el impulso para la aparici\u00f3n de nuevas terapias de ARN para pacientes con enfermedades raras, no solo porque desarrolla sus propias mol\u00e9culas, sino porque se dota de una capacidad para CDMO de oligonucle\u00f3tidos de forma sostenible pionera en Espa\u00f1a.<\/p>\n\t\t\n<style>\n#text-2693104343 {\n  color: #012f5b;\n}\n#text-2693104343 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1112730030 > .col-inner {\n  border-radius: 10px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-873049534\" class=\"col medium-5 small-12 large-5\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t\t\t\n\n  \n    <div class=\"row large-columns-1 medium-columns- small-columns-\" >\n  <div class=\"gallery-col col\" >\n          <div class=\"col-inner\">\n            <a class=\"image-lightbox lightbox-gallery\" href=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449.png\" title=\"\">            <div class=\"box has-hover gallery-box box-overlay dark\">\n              <div class=\"box-image\" >\n                <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"266\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-300x266.png\" class=\"attachment-medium size-medium\" alt=\"\" ids=\"172\" lightbox_image_size=\"original\" columns=\"1\" image_overlay=\"rgba(255, 255, 255, 0)\" srcset=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-300x266.png 300w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-1024x908.png 1024w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-768x681.png 768w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449.png 1060w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>                                  <div class=\"overlay fill\"\n                      style=\"background-color: rgba(255, 255, 255, 0)\">\n                  <\/div>\n                                                              <\/div>\n              <div class=\"box-text text-left\" >\n                 <p><\/p>\n              <\/div>\n            <\/div>\n            <\/a>          <\/div>\n         <\/div><\/div>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-873049534 > .col-inner {\n  border-radius: 10px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n<style>\n#row-1567721791 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n\t\n<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n\t<div id=\"gap-1636687630\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1636687630 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-1571098733 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_1899264283 {\n  padding-top: 0px;\n  padding-bottom: 0px;\n  background-color: #012f5b;\n}\n#section_1899264283 .ux-shape-divider--top svg {\n  height: 30px;\n  --divider-top-width: 100%;\n}\n#section_1899264283 .ux-shape-divider--top .ux-shape-fill {\n  fill: #b9d63e;\n}\n#section_1899264283 .ux-shape-divider--bottom svg {\n  height: 30px;\n  --divider-width: 100%;\n}\n#section_1899264283 .ux-shape-divider--bottom .ux-shape-fill {\n  fill: #bad63d;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section show-for-small\" id=\"section_1152889698\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\t<div class=\"ux-shape-divider ux-shape-divider--top ux-shape-divider--style-waves-opacity-2 ux-shape-divider--flip ux-shape-divider--to-front\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t<div class=\"ux-shape-divider ux-shape-divider--bottom ux-shape-divider--style-waves-opacity-2 ux-shape-divider--flip ux-shape-divider--to-front\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row row-collapse row-full-width align-middle\"  id=\"row-887321381\">\n\n\t<div id=\"col-1116181173\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:#012f5b;\" >\n\t\t\t\n\t\t\t\n<div class=\"row row-collapse row-full-width align-middle align-center\"  id=\"row-8236945\">\n\n\t<div id=\"col-1499916886\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner text-left\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-3382247930\" class=\"text\">\n\t\t\n<h2 style=\"text-align: center;\"><span data-text-color=\"secondary\">F\u00e1rmacos basados en RNA<\/span><\/h2>\n\t\t\n<style>\n#text-3382247930 {\n  text-align: center;\n  color: #5f5e5c;\n}\n#text-3382247930 > * {\n  color: #5f5e5c;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-8236945 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n<div class=\"row row-collapse row-full-width align-middle\"  id=\"row-1053744408\">\n\n\t<div id=\"col-2005538311\" class=\"col medium-12 small-12 large-5\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-3782333058\" class=\"text\">\n\t\t\n<p><strong>Las terapias basadas en oligonucle\u00f3tidos han supuesto una revoluci\u00f3n en la medicina<\/strong> debido a su capacidad para controlar con precisi\u00f3n la producci\u00f3n de una prote\u00edna asociada a una enfermedad, corregir una mutaci\u00f3n y dirigirse a una variedad de v\u00edas y dianas terap\u00e9uticas antes sin opciones de tratamiento.<\/p>\n<p>La elevada tasa de \u00e9xito de las autoridades reguladoras a la hora de aprobar este tipo de medicamentos demuestra esta r\u00e1pida expansi\u00f3n (FDA y EMA). <strong>Las terapias basadas en RNA han producido recientemente tratamientos aprobados por la FDA y la EMA para trastornos metab\u00f3licos y degenerativos extremadamente raros que abordan de forma significativa necesidades m\u00e9dicas no cubiertas y tienen un alto valor terap\u00e9utico<\/strong> (coste anual del tratamiento entre 400 000 y 800 000 euros). De hecho, se ha progresado hasta el punto de que, en los \u00faltimos cinco a\u00f1os, se han autorizado medicamentos cada a\u00f1o, lo que representa el 7% de los medicamentos aprobados por la FDA en 2023.<\/p>\n\t\t\n<style>\n#text-3782333058 {\n  color: rgb(255,255,255);\n}\n#text-3782333058 > * {\n  color: rgb(255,255,255);\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-560461314\" class=\"col medium-12 large-7\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t\t\t\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_551355859\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"3022\" height=\"806\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602.png\" class=\"attachment-original size-original\" alt=\"\" srcset=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602.png 3022w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-300x80.png 300w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-1024x273.png 1024w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-768x205.png 768w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-1536x410.png 1536w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/grafico_a-e1736425393602-2048x546.png 2048w\" sizes=\"auto, (max-width: 3022px) 100vw, 3022px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_551355859 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-779270685\" class=\"text\">\n\t\t\n<p><span style=\"font-size: 90%;\">* Infograf\u00eda extra\u00edda de la <strong>gu\u00eda <em>Descubriendo los oligonucle\u00f3tidos terap\u00e9uticos <\/em>de OLIGOFASTX<\/strong><\/span><\/p>\n\t\t\n<style>\n#text-779270685 {\n  text-align: left;\n  color: #012f5b;\n}\n#text-779270685 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n<a href=\"https:\/\/oligofastx.com\/es\/descubriendo-oligonucleotidos\/\" target=\"_blank\" class=\"button secondary\" rel=\"noopener\"  style=\"border-radius:99px;\">\n\t\t<span>acceder a la descarga de la gu\u00eda<\/span>\n\t<\/a>\n\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-560461314 > .col-inner {\n  padding: 1% 1% 1% 1%;\n  border-radius: 10px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n<style>\n#row-1053744408 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n<div class=\"row row-collapse row-full-width\"  id=\"row-1223156591\">\n\n\t<div id=\"col-1373182688\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"accordion acordeoncolor\">\n\t<div id=\"accordion-1303142777\" class=\"accordion-item\">\n\t\t<a id=\"accordion-1303142777-label\" class=\"accordion-title plain\" href=\"#accordion-item-m\u00e1s-informaci\u00f3n\" aria-expanded=\"false\" aria-controls=\"accordion-1303142777-content\" >\n\t\t\t<button class=\"toggle\" aria-label=\"Toggle\"><i class=\"icon-angle-down\"><\/i><\/button>\n\t\t\t<span>M\u00e1s informaci\u00f3n<\/span>\n\t\t<\/a>\n\t\t<div id=\"accordion-1303142777-content\" class=\"accordion-inner\" aria-labelledby=\"accordion-1303142777-label\" >\n\t\t\t\n<div class=\"row row-small row-full-width align-equal\"  id=\"row-887889187\">\n\n\t<div id=\"col-1129629684\" class=\"col medium-7 small-12 large-7\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t\t\t\n\t<div id=\"text-1692674008\" class=\"text\">\n\t\t\n<p>El compromiso adquirido por las agencias reguladoras tanto europeas como norteamericanas con las terapias con oligonucle\u00f3tidos de ARN para el tratamiento de enfermedades raras y <strong>la legislaci\u00f3n articulada como el Reglamento 141\/2000 de la Ley de Medicamentos Hu\u00e9rfanos en la UE, ha dado lugar a cientos de nuevos medicamentos hu\u00e9rfanos, la mayor\u00eda enfermedades raras<\/strong>. Las terapias basadas en oligonucle\u00f3tidos son una de las mejores herramientas para el desarrollo de terapias que satisfagan las necesidades de enfermedades raras muy complejas, gracias a su versatilidad y especificidad, y se ha abierto un camino sin retorno.<\/p>\n\t\t\n<style>\n#text-1692674008 {\n  color: #012f5b;\n}\n#text-1692674008 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"text-1653856837\" class=\"text\">\n\t\t\n<p><strong>En la actualidad hay 21 medicamentos basados en oligonucle\u00f3tidos aprobados para muchas enfermedades diferentes y muchos m\u00e1s en fase de investigaci\u00f3n<\/strong>. La misi\u00f3n de Sylentis con SYOLIGO sopone el impulso para la aparici\u00f3n de nuevas terapias de ARN para pacientes con enfermedades raras, no solo porque desarrolla sus propias mol\u00e9culas, sino porque se dota de una capacidad para CDMO de oligonucle\u00f3tidos de forma sostenible pionera en Espa\u00f1a.<\/p>\n\t\t\n<style>\n#text-1653856837 {\n  color: #012f5b;\n}\n#text-1653856837 > * {\n  color: #012f5b;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1129629684 > .col-inner {\n  border-radius: 10px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-299704643\" class=\"col medium-5 small-12 large-5\"  >\n\t\t\t\t<div class=\"col-inner\" style=\"background-color:rgb(255,255,255);\" >\n\t\t\t\n\t\t\t\n\n  \n    <div class=\"row large-columns-1 medium-columns- small-columns-\" >\n  <div class=\"gallery-col col\" >\n          <div class=\"col-inner\">\n            <a class=\"image-lightbox lightbox-gallery\" href=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449.png\" title=\"\">            <div class=\"box has-hover gallery-box box-overlay dark\">\n              <div class=\"box-image\" >\n                <img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"266\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-300x266.png\" class=\"attachment-medium size-medium\" alt=\"\" ids=\"172\" lightbox_image_size=\"original\" columns=\"1\" image_overlay=\"rgba(255, 255, 255, 0)\" srcset=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-300x266.png 300w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-1024x908.png 1024w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449-768x681.png 768w, https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/indicaciones-terapeuticas-e1736426277449.png 1060w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>                                  <div class=\"overlay fill\"\n                      style=\"background-color: rgba(255, 255, 255, 0)\">\n                  <\/div>\n                                                              <\/div>\n              <div class=\"box-text text-left\" >\n                 <p><\/p>\n              <\/div>\n            <\/div>\n            <\/a>          <\/div>\n         <\/div><\/div>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-299704643 > .col-inner {\n  border-radius: 10px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n<style>\n#row-887889187 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n\t\n<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n\t<div id=\"gap-886270103\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-886270103 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-887321381 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t\t<\/div>\n\n\t\t\n<style>\n#section_1152889698 {\n  padding-top: 0px;\n  padding-bottom: 0px;\n  background-color: #012f5b;\n}\n#section_1152889698 .ux-shape-divider--top svg {\n  height: 30px;\n  --divider-top-width: 100%;\n}\n#section_1152889698 .ux-shape-divider--top .ux-shape-fill {\n  fill: #b9d63e;\n}\n#section_1152889698 .ux-shape-divider--bottom svg {\n  height: 30px;\n  --divider-width: 100%;\n}\n#section_1152889698 .ux-shape-divider--bottom .ux-shape-fill {\n  fill: #bad63d;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section hide-for-small\" id=\"section_604161117\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t<div class=\"section-bg-overlay absolute fill\"><\/div>\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\t<div class=\"ux-shape-divider ux-shape-divider--top ux-shape-divider--style-waves-opacity-2 ux-shape-divider--flip\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t<div class=\"ux-shape-divider ux-shape-divider--bottom ux-shape-divider--style-waves-opacity-2\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row row-collapse align-center\" style=\"max-width:80%\" id=\"row-809915666\">\n\n\t<div id=\"col-1769040024\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n<h2 style=\"text-align: center;\"><span data-text-color=\"success\">Producci\u00f3n sostenible de oligonucle\u00f3tidos terap\u00e9uticos<\/span><\/h2>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1769040024 > .col-inner {\n  padding: 5% 0px 2% 0px;\n}\n@media (min-width:850px) {\n  #col-1769040024 > .col-inner {\n    padding: 50px 0px 50px 0px;\n  }\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row row-collapse align-equal\" style=\"max-width:80%\" id=\"row-1654549062\">\n\n\t<div id=\"col-1727725611\" class=\"col medium-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-4072257816\" class=\"text\">\n\t\t\n<p>Los procesos actuales de s\u00edntesis de oligonucle\u00f3tidos presentan desaf\u00edos significativos en t\u00e9rminos de sostenibilidad. La s\u00edntesis qu\u00edmica convencional, que utiliza m\u00e9todos de fosforamiditos, genera altos vol\u00famenes de residuos qu\u00edmicos, como disolventes y reactivos peligrosos, que requieren gesti\u00f3n especializada. Adem\u00e1s, los m\u00e9todos tradicionales consumen grandes cantidades de energ\u00eda. Este modelo no es compatible con un crecimiento continuo en la demanda sin un impacto ambiental severo, por lo que se hace imprescindible el desarrollo de procesos m\u00e1s limpios y eficientes.<\/p>\n<p>En el \u00e1mbito cient\u00edfico, una soluci\u00f3n prometedora radica en la <strong>optimizaci\u00f3n de los procesos de s\u00edntesis<\/strong>, incluyendo el dise\u00f1o de reacciones que maximicen el rendimiento y minimicen los subproductos. Por ejemplo, el uso de reactivos menos t\u00f3xicos y disolventes verdes podr\u00eda reducir significativamente el impacto ambiental. Paralelamente, se est\u00e1n explorando <strong>enfoques enzim\u00e1ticos<\/strong> para la s\u00edntesis de oligonucle\u00f3tidos, que podr\u00edan ofrecer alternativas m\u00e1s sostenibles al depender de sistemas biocatal\u00edticos espec\u00edficos. Estas t\u00e9cnicas, aunque a\u00fan en etapas de desarrollo, tienen el potencial de transformar la industria al ser inherentemente menos agresivas con el medioambiente. Otro aspecto clave es la integraci\u00f3n de <strong>principios de econom\u00eda circular en la producci\u00f3n de oligonucle\u00f3tidos.<\/strong><\/p>\n\t\t\n<style>\n#text-4072257816 {\n  text-align: left;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-1741340998\" class=\"col medium-12 large-6 medium-col-first\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"slider-wrapper relative\" id=\"slider-705144353\" >\n    <div class=\"slider slider-nav-circle slider-nav-large slider-nav-light slider-style-normal\"\n        data-flickity-options='{\n            \"cellAlign\": \"center\",\n            \"imagesLoaded\": true,\n            \"lazyLoad\": 1,\n            \"freeScroll\": false,\n            \"wrapAround\": true,\n            \"autoPlay\": 6000,\n            \"pauseAutoPlayOnHover\" : true,\n            \"prevNextButtons\": false,\n            \"contain\" : true,\n            \"adaptiveHeight\" : true,\n            \"dragThreshold\" : 10,\n            \"percentPosition\": true,\n            \"pageDots\": false,\n            \"rightToLeft\": false,\n            \"draggable\": true,\n            \"selectedAttraction\": 0.1,\n            \"parallax\" : 0,\n            \"friction\": 0.6        }'\n        >\n        \n\n  <div class=\"banner has-hover\" id=\"banner-1575662364\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1900\" height=\"1188\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/produccion-sostenible-oligos-syoligo-2.jpg\" class=\"bg attachment-original size-original\" alt=\"\" \/>                                    \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n   <div id=\"text-box-150290786\" class=\"text-box banner-layer x50 md-x50 lg-x50 y50 md-y50 lg-y50 res-text\">\n                                <div class=\"text-box-content text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n              <\/div>\n           <\/div>\n                            \n<style>\n#text-box-150290786 {\n  width: 60%;\n}\n#text-box-150290786 .text-box-content {\n  font-size: 100%;\n}\n@media (min-width:550px) {\n  #text-box-150290786 {\n    width: 60%;\n  }\n}\n<\/style>\n    <\/div>\n \n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1575662364 {\n  padding-top: 200px;\n}\n@media (min-width:850px) {\n  #banner-1575662364 {\n    padding-top: 500px;\n  }\n}\n<\/style>\n  <\/div>\n\n\n     <\/div>\n\n     <div class=\"loading-spin dark large centered\"><\/div>\n\n\t<\/div>\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-1654549062 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t<div id=\"gap-1994325519\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1994325519 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-1719472477\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1719472477 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\n\t\t\n<style>\n#section_604161117 {\n  padding-top: 0px;\n  padding-bottom: 0px;\n  background-color: #f5f5f5;\n}\n#section_604161117 .section-bg-overlay {\n  background-color: rgba(255, 255, 255, 0.85);\n}\n#section_604161117 .ux-shape-divider--top svg {\n  height: 30px;\n  --divider-top-width: 100%;\n}\n#section_604161117 .ux-shape-divider--top .ux-shape-fill {\n  fill: #b9d63e;\n}\n#section_604161117 .ux-shape-divider--bottom svg {\n  height: 30px;\n  --divider-width: 100%;\n}\n#section_604161117 .ux-shape-divider--bottom .ux-shape-fill {\n  fill: #bad63d;\n}\n<\/style>\n\t<\/section>\n\t\n\n\t<section class=\"section show-for-small\" id=\"section_1742785238\">\n\t\t<div class=\"section-bg fill\" >\n\t\t\t\t\t\t\t\t\t<div class=\"section-bg-overlay absolute fill\"><\/div>\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\t<div class=\"ux-shape-divider ux-shape-divider--top ux-shape-divider--style-waves-opacity-2 ux-shape-divider--flip\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t<div class=\"ux-shape-divider ux-shape-divider--bottom ux-shape-divider--style-waves-opacity-2\">\n\t\t<svg viewBox=\"0 0 1000 300\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" preserveAspectRatio=\"none\">\n  <path class=\"ux-shape-fill\" opacity=\"0.15\" d=\"M0 299L-2 19.9998C153 -16.0002 308 155 413 184C515.64 212.35 562 152 645 153C725 154 787 206 874 233C939.54 253.34 975 248 1000 244.61V299H0Z\"\/>\n  <path class=\"ux-shape-fill\" opacity=\"0.3\" d=\"M0 300L-2 34C155 -9.00003 300 178 403 212C504.11 245.38 562 165 645 166C725 167 790.09 220.07 874 253C939.21 278.59 978.07 269.72 1000 263.61V300H0Z\"\/>\n  <path class=\"ux-shape-fill\" d=\"M0 300L-1 69.7099C216 56.9999 299.47 198.86 403 226C506 253 577 196 660 197C740 198 790.09 234.07 874 267C935.23 291 982 282.61 1000 277.61V300H0Z\"\/>\n<\/svg>\n\t<\/div>\n\n\t\t<div class=\"section-content relative\">\n\t\t\t\n<div class=\"row row-collapse align-center\" style=\"max-width:80%\" id=\"row-88154117\">\n\n\t<div id=\"col-261820967\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n<h2 style=\"text-align: center;\"><span data-text-color=\"success\">Producci\u00f3n sostenible de oligonucle\u00f3tidos terap\u00e9uticos<\/span><\/h2>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-261820967 > .col-inner {\n  padding: 5% 0px 2% 0px;\n}\n@media (min-width:850px) {\n  #col-261820967 > .col-inner {\n    padding: 50px 0px 50px 0px;\n  }\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row row-collapse row-full-width align-equal\"  id=\"row-29144301\">\n\n\t<div id=\"col-1646604425\" class=\"col medium-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"text-226690955\" class=\"text\">\n\t\t\n<p>Los procesos actuales de s\u00edntesis de oligonucle\u00f3tidos presentan desaf\u00edos significativos en t\u00e9rminos de sostenibilidad. La s\u00edntesis qu\u00edmica convencional, que utiliza m\u00e9todos de fosforamiditos, genera altos vol\u00famenes de residuos qu\u00edmicos, como disolventes y reactivos peligrosos, que requieren gesti\u00f3n especializada. Adem\u00e1s, los m\u00e9todos tradicionales consumen grandes cantidades de energ\u00eda. Este modelo no es compatible con un crecimiento continuo en la demanda sin un impacto ambiental severo, por lo que se hace imprescindible el desarrollo de procesos m\u00e1s limpios y eficientes.<\/p>\n<p>En el \u00e1mbito cient\u00edfico, una soluci\u00f3n prometedora radica en la <strong>optimizaci\u00f3n de los procesos de s\u00edntesis<\/strong>, incluyendo el dise\u00f1o de reacciones que maximicen el rendimiento y minimicen los subproductos. Por ejemplo, el uso de reactivos menos t\u00f3xicos y disolventes verdes podr\u00eda reducir significativamente el impacto ambiental. Paralelamente, se est\u00e1n explorando <strong>enfoques enzim\u00e1ticos<\/strong> para la s\u00edntesis de oligonucle\u00f3tidos, que podr\u00edan ofrecer alternativas m\u00e1s sostenibles al depender de sistemas biocatal\u00edticos espec\u00edficos. Estas t\u00e9cnicas, aunque a\u00fan en etapas de desarrollo, tienen el potencial de transformar la industria al ser inherentemente menos agresivas con el medioambiente. Otro aspecto clave es la integraci\u00f3n de <strong>principios de econom\u00eda circular en la producci\u00f3n de oligonucle\u00f3tidos.<\/strong><\/p>\n\t\t\n<style>\n#text-226690955 {\n  text-align: left;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\t<div id=\"col-683018229\" class=\"col medium-12 large-6 medium-col-first\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"slider-wrapper relative\" id=\"slider-2090162913\" >\n    <div class=\"slider slider-nav-circle slider-nav-large slider-nav-light slider-style-normal\"\n        data-flickity-options='{\n            \"cellAlign\": \"center\",\n            \"imagesLoaded\": true,\n            \"lazyLoad\": 1,\n            \"freeScroll\": false,\n            \"wrapAround\": true,\n            \"autoPlay\": 6000,\n            \"pauseAutoPlayOnHover\" : true,\n            \"prevNextButtons\": false,\n            \"contain\" : true,\n            \"adaptiveHeight\" : true,\n            \"dragThreshold\" : 10,\n            \"percentPosition\": true,\n            \"pageDots\": false,\n            \"rightToLeft\": false,\n            \"draggable\": true,\n            \"selectedAttraction\": 0.1,\n            \"parallax\" : 0,\n            \"friction\": 0.6        }'\n        >\n        \n\n  <div class=\"banner has-hover\" id=\"banner-958540886\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1900\" height=\"1188\" src=\"https:\/\/syoligo.sylentis.com\/wp-content\/uploads\/2025\/01\/produccion-sostenible-oligos-syoligo-2.jpg\" class=\"bg attachment-original size-original\" alt=\"\" \/>                                    \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n   <div id=\"text-box-863153658\" class=\"text-box banner-layer x50 md-x50 lg-x50 y50 md-y50 lg-y50 res-text\">\n                                <div class=\"text-box-content text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n              <\/div>\n           <\/div>\n                            \n<style>\n#text-box-863153658 {\n  width: 60%;\n}\n#text-box-863153658 .text-box-content {\n  font-size: 100%;\n}\n@media (min-width:550px) {\n  #text-box-863153658 {\n    width: 60%;\n  }\n}\n<\/style>\n    <\/div>\n \n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-958540886 {\n  padding-top: 200px;\n}\n@media (min-width:850px) {\n  #banner-958540886 {\n    padding-top: 500px;\n  }\n}\n<\/style>\n  <\/div>\n\n\n     <\/div>\n\n     <div class=\"loading-spin dark large centered\"><\/div>\n\n\t<\/div>\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<style>\n#row-29144301 > .col > .col-inner {\n  padding: 3% 3% 3% 3%;\n}\n<\/style>\n<\/div>\n\t<div id=\"gap-1151185825\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1151185825 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\t<div id=\"gap-1628959499\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1628959499 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\t\t<\/div>\n\n\t\t\n<style>\n#section_1742785238 {\n  padding-top: 0px;\n  padding-bottom: 0px;\n  background-color: #f5f5f5;\n}\n#section_1742785238 .section-bg-overlay {\n  background-color: rgba(255, 255, 255, 0.85);\n}\n#section_1742785238 .ux-shape-divider--top svg {\n  height: 30px;\n  --divider-top-width: 100%;\n}\n#section_1742785238 .ux-shape-divider--top .ux-shape-fill {\n  fill: #b9d63e;\n}\n#section_1742785238 .ux-shape-divider--bottom svg {\n  height: 30px;\n  --divider-width: 100%;\n}\n#section_1742785238 .ux-shape-divider--bottom .ux-shape-fill {\n  fill: #bad63d;\n}\n<\/style>\n\t<\/section>\n\t\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-transparent-header.php","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"class_list":["post-20","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/pages\/20","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/comments?post=20"}],"version-history":[{"count":57,"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/pages\/20\/revisions"}],"predecessor-version":[{"id":623,"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/pages\/20\/revisions\/623"}],"wp:attachment":[{"href":"https:\/\/syoligo.sylentis.com\/es\/wp-json\/wp\/v2\/media?parent=20"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}